GlassScriptPhysician profile
Robert R Coleman
NPI 1134357015
$1,313.69
in general payments reported to CMS, 2019-2025
24 companies · $727 in 2025
The $727 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.67 · 2020: $59.98 · 2023: $56.31 · 2024: $378 · 2025: $727.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $272.49 | 2024-2025 | General - Dbs |
| Abbvie INC. | $242.58 | 2024-2025 | |
| Ucb, INC. | $207.61 | 2025 | Fintepla, Briviact, Nayzilam |
| Jazz Pharmaceuticals INC. | $47.97 | 2025 | |
| Amneal Pharmaceuticals LLC | $42.81 | 2024 | Crexont, Rytary |
| Mdd US Operations, LLC | $42.01 | 2019 | |
| Acorda Therapeutics, INC | $40.56 | 2020 | |
| Neurelis, INC. | $38.49 | 2025 | Valtoco |
| Aucta Pharmaceuticals, INC. | $37.26 | 2025 | Motpoly Xr |
| Acadia Pharmaceuticals INC | $35.96 | 2024-2025 | Nuplazid |
| Revance Therapeutics, INC. | $30.10 | 2024 | Daxxify |
| Teva Pharmaceuticals USA, INC. | $29.17 | 2023 | Austedo |
| Medtronic USA, INC. | $29.10 | 2019 | |
| Upsher-Smith Laboratories LLC | $29.00 | 2025 | |
| Xeris Pharmaceuticals, INC. | $27.79 | 2025 | Keveyis |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cala Health, INC. | $27.14 | 2023 | Cala Trio, Cala Kiq |
| Supernus Pharmaceuticals, INC. | $26.16 | 2025 | |
| Pfizer INC. | $23.87 | 2024 | |
| Medtronic, INC. | $22.93 | 2025 | Percept PC Brainsense |
| Abbott Laboratories | $21.56 | 2019 | |
| Otter Pharmaceuticals, LLC | $19.71 | 2025 | Sympazan |
| E.R. Squibb & Sons, L.L.C. | $19.42 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Coleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.